<DOC>
	<DOCNO>NCT02528799</DOCNO>
	<brief_summary>A randomized , double-blind , placebo-controlled , dose titration trial , stratify Human Leukocyte Antigen ( HLA ) -DQ2.5 genotype subject celiac disease .</brief_summary>
	<brief_title>Safety Tolerability Nexvax2 Subjects With Celiac Disease</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled , study evaluate safety tolerability Nexvax2 precede dose titration period patient celiac disease currently gluten-free diet . The study consist Screening Period , Treatment Period , Follow-up Period . Eligible subject enrol one three cohort accord whether homozygous homozygous gene cod HLA-DQ2.5 .</detailed_description>
	<mesh_term>Celiac Disease</mesh_term>
	<criteria>1 . Subject sign understands informed consent form initiation study specific procedure . 2 . Subject 18 70 year old ( inclusive ) date Screening Visit . 3 . Subject diagnosed celiac disease basis intestinal histology show villous atrophy accord expert guideline current time diagnosis . 4 . Subject HLA DQ2.5 genotype ( HLADQA1*05 HLADQB1*02 ) . 1 . Subject maintain glutenfree diet least 1 year . 2 . Celiac Dietary Adherence Test screen indicates noncompliance glutenfree diet ( score &gt; 12 ) . 3 . Serum level recombinant human transglutaminase ( tTG ) specific immunoglobulinA ( IgA ) deamidated gliadin peptide ( DGP ) specific immunoglobulinG ( IgG ) elevate manufacturer 's upper limit normal . The elevation one serology test tTG IgA DGP IgG exclusion . 4 . Subject uncontrolled complication celiac disease medical condition , opinion investigator , would impact immune response pose increase risk subject . 5 . Subject use immunomodulatory immune suppress medical treatment 2 month prior Screening , example azathioprine , methotrexate , biological 6 . Subject female premenopausal perimenopausal male partner sterile , unless sterile , practice true abstinence , unless throughout entire study period 30 day study drug discontinuation use medically acceptable method contraception . 7 . Subject male premenopausal perimenopausal female partner sterile , unless sterile , practice true abstinence , unless throughout entire study period 30 day study drug discontinuation use medically acceptable method contraception , unless female partner use medically acceptable method contraception . 8 . Subject unable and/or unwilling comply study requirement . 9 . Subject take oral parenteral corticosteroid within previous six week prior Screening . Topical inhale corticosteroid acceptable . 10 . Subject receive experimental therapy within 30 day prior Screening . 11 . Subject previously enrol dosed clinical trial Nevax2 . 12 . Subject follow laboratory abnormality Screening : Alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , alkaline phosphatase ( ALP ) ≥ 2 × upper limit normal ( ULN ) Hemoglobin &lt; 10 g/dL Platelet count &lt; 100 × 109/L White blood cell count ( WBC ) outside normal range judge clinically significant investigator Direct bilirubin outside normal range Any clinically significant abnormal laboratory value , determine investigator 13 . Subject lactating , know pregnant , positive pregnancy test Screening Treatment Day , intend become pregnant , nursing . 14 . Subject history presence medically significant condition consider investigator potential adversely affect participation study and/or interpretation study result . 15 . Subject history severe allergic reaction ( e.g. , swell mouth throat , difficulty breathing , hypotension , shock ) require medical intervention . 16 . Subject donate blood ≤ 56 day prior Screening plan donate blood within 5 week study completion . 17 . Subject clinically relevant abnormality electrocardiogram ( ECG ) , determine investigator . 18 . Other unspecified reason opinion investigator sponsor make subject unsuitable enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>